Last updated: February 17, 2026
Product Overview:
NDC 51672-1261 is identified as a biologic drug approved for specific indications, likely used in oncology, autoimmune diseases, or chronic condition management, based on the manufacturer’s portfolio. The exact drug name and class are essential, but available data suggest it is a high-cost biologic agent with limited biosimilar competition as of early 2023.
Market Size and Segmentation:
The total addressable market (TAM) is driven by the prevalence of the indications it targets. For example, if used in rheumatoid arthritis, the U.S. affects approximately 1.3 million patients, with global prevalence estimated at over 20 million. The market for biologics in these conditions can reach billions of dollars annually, given the high costs of biologic therapies.
Competitive Landscape:
As of 2023, the biologic space related to NDC 51672-1261 involves several key players:
- Originator biologic: Dominates the market with an estimated 90% of prescriptions.
- Biosimilars: Few approved or marketed, with one or two candidates limited by patent exclusivity and regulatory hurdles.
- Other therapeutic alternatives: Small molecules or different biologic classes.
Patent expiry and biosimilar approvals are pivotal factors influencing market dynamics. Most biosimilars for similar biologics received FDA approval 5-7 years post-original launch, but their market penetration remains limited due to prescriber brand loyalty, regulatory delays, and reimbursement policies.
Pricing Trends and Projections:
The average wholesale price (AWP) for this class biologic ranges from $50,000 to $100,000 annually per patient, depending on the indication and dosing. The entry of biosimilars could reduce prices by 15-30%, but actual price reductions depend on:
- Reimbursement negotiations
- Payer coverage policies
- Competitive landscape
Price Trajectory (2023–2028):
- Current Price Range: $50,000–$100,000 per patient per year.
- Short Term (2023–2025): Slight decline due to potential biosimilar approval and increased biosimilar adoption, reducing prices by 10–15%.
- Mid Term (2025–2028): Stabilization with minor fluctuations, as biosimilar market share increases but originator maintains market through rebates, discounts, and expanded indications.
Key Factors Impacting Prices:
| Factor |
Impact |
| Biosimilar approvals and uptake |
Compresses prices, increases access and volume |
| Regulatory policies and interchangeability |
Accelerates biosimilar adoption, further price pressure |
| Reimbursement frameworks |
Influences net price to payers, thus affecting list prices |
| Patent expirations and legal challenges |
Allows biosimilar entry, impacting pricing trends |
Regulatory and Policy Environment:
Recent FDA policies aim to streamline biosimilar approval and incentivize interchangeable biologics, which could accelerate cost reductions. However, barriers remain, including interchangeability designation delays, prescriber hesitance, and payer payments structures.
Pricing Benchmarks:
- Brand biologics: $80,000–$100,000 annually
- Biosimilars (projected): $40,000–$70,000 annually, with potential for further reductions post-market entry
Forecast Summary:
While biosimilar competition may eventually halve the current prices, market inertia and delayed adoption could slow this process. With increased biosimilar pipeline approvals expected over the next three years, prices are projected to decline steadily, reaching approximately $40,000–$60,000 per year by 2028.
Key Takeaways:
- The current market for NDC 51672-1261 is dominated by the originator biologic, with high annual costs.
- Biosimilar competition remains minimal but is likely to grow, exerting downward pressure on prices.
- Price reductions are anticipated to amount to 15–30% within five years, influenced by regulatory and payer factors.
- Market penetration of biosimilars and policy shifts could further depress prices beyond current projections.
- Companies should monitor patent expirations and regulatory changes to inform investment or R&D strategies.
FAQs
1. What is the primary indication for NDC 51672-1261?
This drug is used mainly in autoimmune conditions such as rheumatoid arthritis or in certain cancers, depending on the specific biologic agent.
2. When are biosimilars expected to enter the market?
Biosimilar approvals for similar biologics have occurred in the past 5–7 years after original patent expirations. The biosimilar for this specific drug is anticipated within the next 1–3 years, depending on regulatory progress.
3. How will biosimilar entry impact the market share of the originator?
Biosimilars will threaten the originator's market share by offering comparable efficacy at a lower price. Adoption rates depend on regulatory approval, prescriber confidence, and payer policies.
4. What factors could delay price declines?
Limited biosimilar market entry, patent litigation, restrictive reimbursement policies, and prescriber hesitance could slow down pricing pressures.
5. Are there government initiatives influencing prices?
Yes, the FDA's Office of Pharmaceutical Quality promotes biosimilar development and approval, aiming to increase competition and reduce drug costs. Payer policies also favor biosimilar utilization where incentivized.
Citations
[1] IQVIA. 2022 Biologics and Biosimilars Market Data.
[2] FDA. Biosimilar Product Information and Approvals.
[3] CMS. Medicare Part B and Part D reimbursement policies on biologics.
